3145 results for «318»
3145 results
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing transcatheter aortic valve implantation (TAVI) with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasizing...
Mastering mitral TEER: guidelines, complex cases, and Asia Pacific insights
14 Feb 2026 – From PCR Tokyo Valves 2026
Focused on mastering mitral transcatheter edge-to-edge repair (TEER), this session analyzed the 2025 ESC VHD guidelines and their clinical implications. It addressed optimal timing and treatment strategies for severe heart failure beyond the COAPT trial and explored technical solutions for complex anatomies, including customization approaches for...
Coronary access and revascularisation in patients undergoing TAVI: from work-up to lifetime management
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...
TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation
04 Nov 2024
Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.
Also watch the interview with Susheel K. Kodali
Author
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...
Author
Author
